EHA 2023 | Gemtuzumab-based induction chemotherapy with midostaurin in FLT3-mutated AML
Nigel Russell, MD, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the results of the AML19V2 “Midotarg” pilot trial evaluating the safety and efficacy of combining gemtuzumab ozogamicin (GO) in a single or fractionated dose with induction chemotherapy and midostaurin for newly diagnosed FLT3-mutated acute myeloid leukemia (AML). The addition of midostaurin to gemtuzumab-based induction chemotherapy was well-tolerated, with no treatment-related mortality. The fractionated schedule of GO resulted in a higher measurable residual disease (MRD) negativity rate. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Jazz Pharmaceuticals
